Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy
2009 ◽
Vol 28
(3)
◽
pp. 246-248
◽
2009 ◽
Vol 28
(6)
◽
pp. 488-492
◽
2007 ◽
Vol 2007
◽
pp. 155-156
2007 ◽
Vol 18
(5)
◽
pp. 343-346
◽